Should I Buy MYNZ? MYNZ 2026 Analysis

Should You Buy Mainz Biomed NV (MYNZ) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

1.190

1 Day change

-4.03%

52 Week Range

8.200

Analysis Updated At

2026/01/30

Not a good buy right now for an impatient trader. MYNZ is showing mildly improving momentum (positive MACD, neutral RSI), but there is no Intellectia buy signal, no near-term news catalyst, and the stock is trading below the key pivot (1.291) in pre-market (1.22). With weak/unchanged growth trends and persistent losses, the setup lacks a strong trigger for an immediate upside move. I would avoid initiating a new position at this moment.

Technical Analysis

Trend/Momentum: MACD histogram is positive (0.00712) and expanding, which supports a short-term bullish bias. RSI(6) at ~57 is neutral-to-slightly bullish, not overbought. Moving Averages: Converging MAs suggest consolidation rather than a clear trend—price likely needs a breakout to confirm direction. Key Levels: Pre-market 1.22 is below Pivot 1.291 (near-term overhead). Support sits at S1 1.093 then S2 0.97; resistance at R1 1.49 then R2 1.613. A stronger technical “buy now” case would typically require reclaiming/holding above ~1.29 and pushing toward 1.49. Pattern/Forward Odds: Similar candlestick-pattern analog suggests only a 30% chance of small gains (about +1.52% next day; +4.67% next week; +3.42% next month), which is not compelling for an immediate-entry trader. Intellectia Proprietary Trading Signals - [AI Stock Picker](module://ai_stock_pick): No signal on given stock today. - [SwingMax](module://swingmax): No signal on given stock today.

Options Data

Positive Catalysts

and holds, it could attract momentum buyers toward 1.
No heavy hedge fund/insider selling trend indicated (both neutral).

Neutral/Negative Catalysts

No news in the last week: no clear event-driven catalyst to force an immediate move.
Price is below the Pivot (1.291), implying overhead supply/resistance nearby.
No Intellectia AI Stock Picker or SwingMax entry signal—reduces conviction for a “buy right now” decision.
Financials show ongoing material losses with minimal revenue base, which can weigh on sentiment and limit sustained rallies.

Financial Performance

Latest provided quarter: 2023/Q4. Revenue was 214,761 (reported as 0.00% YoY change), gross margin 62.74%. Net income remained deeply negative at -5,183,327 (also shown as 0.00% YoY change), and EPS was -0.27. Overall: very small revenue base and continuing losses with no clear acceleration in growth in the provided snapshot.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating/price target change data was provided, so there is no identifiable recent trend in Wall Street upgrades/downgrades or target revisions. Pros (typical bull view): potential upside if momentum builds and the stock breaks above key resistance. Cons (typical bear view): lack of catalysts and persistent losses/limited revenue scale make it harder to justify an aggressive buy right now. Politicians/Congress: No recent congress trading data available, and no politician/influential-figure transaction data was provided.

1 Analyst Rating

Wall Street analysts forecast MYNZ stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MYNZ is 14 USD with a low forecast of 14 USD and a high forecast of 14 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 1.240

Low

Averages

High

Current: 1.240

Low

Averages

High

Maxim Group

Michael Okunewitch

Strong Buy

Initiates

$14

AI Analysis

2025-02-14

Reason